Synthetic Microbial Therapeutics for the Targeted Elimination of Antibiotic-Resistant Bacteria
Cheyenne McBane
Antimicrobial resistance (AMR) is a growing worldwide concern because it threatens global health. The increase in antimicrobial resistance is attributed to the rapid evolution of bacteria, the ability of bacteria to transfer genes among themselves, and the ongoing selective pressure from the continued use of antimicrobials. New antibiotic development and/or combination therapy approaches are no longer adequate due to the increasing prevalence of multiple drug-resistant organisms. I propose that there is a way to produce engineered microbial systems that can serve as programmable therapeutic agents and can detect AMR bacteria and kill them without damaging healthy commensal microbes in our body. The engineered microbes could have pathogen detection capabilities through pathogen-sensing modules that respond to quorum-sensing signals and genetic markers indicating AMR and have the ability to produce bacteriocins, disrupt quorum sensing, and use CRISPR for the degradation of resistance genes through effector modules. These engineered microbes would act as autonomous and self-regulating therapeutic agents, enabling the targeted inhibition of AMR pathogens while avoiding any significant disruption of the normal microbiome. Thus, these systems could represent a shift from traditional antimicrobial drug development to adaptive and biologically adaptive antimicrobial systems.
Abstract
Antimicrobial resistance (AMR) is a growing worldwide concern because it threatens global health. The increase in antimicrobial resistance is attributed to the rapid evolution of bacteria, the ability of bacteria to transfer genes among themselves, and the ongoing selective pressure from the continued use of antimicrobials. New antibiotic development and/or combination therapy approaches are no longer adequate due to the increasing prevalence of multiple drug-resistant organisms. I propose that there is a way to produce engineered microbial systems that can serve as programmable therapeutic agents and can detect AMR bacteria and kill them without damaging healthy commensal microbes in our body. The engineered microbes could have pathogen detection capabilities through pathogen-sensing modules that respond to quorum-sensing signals and genetic markers indicating AMR and have the ability to produce bacteriocins, disrupt quorum sensing, and use CRISPR for the degradation of resistance genes through effector modules. These engineered microbes would act as autonomous and self-regulating therapeutic agents, enabling the targeted inhibition of AMR pathogens while avoiding any significant disruption of the normal microbiome. Thus, these systems could represent a shift from traditional antimicrobial drug development to adaptive and biologically adaptive antimicrobial systems.
Claimed statement
Unresolved
Assumptions
Unresolved
Canonical statement
Unresolved
Difference from canonical
Unresolved
References
CRISPR–Cas therapies targeting bacteria. 10.1038/s44222-025-00311-8. Nature Reviews Bioengineering
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. 10.1038/nbt.3043. Nature Biotechnology
Molecular mechanisms of antibiotic resistance. 10.1038/nrmicro3380. Nature Reviews Microbiology
Developing a new class of engineered live bacterial therapeutics to treat human diseases. 10.1038/s41467-020-15508-1. Nature Communications
Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. 10.1038/nbt.3011. Nature Biotechnology
Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox. 10.1016/j.tibtech.2018.09.005. Trends in Biotechnology
Programmable probiotics for detection of cancer in urine. 10.1126/scitranslmed.aaa3519. Science Translational Medicine
Molecular mechanisms of antibiotic resistance revisited. 10.1038/s41579-022-00820-y. Nature Reviews Microbiology
Synchronized cycles of bacterial lysis for in vivo delivery. 10.1038/nature18930. Nature
Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. 10.1038/ncomms15028. Nature Communications
Synthetic Biology Approaches in the Development of Engineered Therapeutic Microbes. 10.3390/ijms21228744. International Journal of Molecular Sciences
Programming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut Microbiota. 10.1016/j.cels.2015.06.001. Cell Systems
Engineering bacteria for diagnostic and therapeutic applications. 10.1038/nrmicro.2017.172. Nature Reviews Microbiology
CRISPR-based genomic tools for the manipulation of genetically intractable microorganisms. 10.1038/s41579-018-0002-7. Nature Reviews Microbiology
CRISPR — a widespread system that provides acquired resistance against phages in bacteria and archaea. 10.1038/nrmicro1793. Nature Reviews Microbiology